TY - JOUR
T1 - Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer
T2 - A case report and literature review
AU - Wu, Fengying
AU - Zhang, Shijia
AU - Gao, Guanghui
AU - Zhao, Jing
AU - Ren, Shengxiang
AU - Zhou, Caicun
N1 - Funding Information:
National Natural Science Foundation of China (Grant No. 81402381).
Publisher Copyright:
© 2018 Taylor & Francis Group, LLC.
PY - 2018/3/4
Y1 - 2018/3/4
N2 - Although targeted therapy directed toward driver mutations has produced a significant efficacy benefit for patients with non-small cell lung cancer (NSCLC), many patients do not possess mutations associated with the approved targeted drugs. Angiogenic agents play an important role in the therapeutic strategy for advanced NSCLC. Apatinib is a novel tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2. A phase II clinical trial demonstrated the survival benefit of apatinib monotherapy in advanced NSCLC. Moreover, addition of anti-angiogenic agents to chemotherapy showed robust efficacy in advanced NSCLC, regardless of tumor histology. Here, we present the case of a heavily pretreated lung adenocarcinoma patient who was treated with apatinib and apatinib continuation plus docetaxel re-challenge. He was negative for several driver genes, including EGFR, ALK, KRAS, ROS1, HER2, RET and BRAF. The previous treatment included platinum-based doublets, pemetrexed monotherapy, docetaxel plus bevacizumab, gefitinib monotherapy, nab-paclitaxel monotherapy, irinotecan plus oxaliplatin and radiotherapy. He obtained a partial response after both apatinib monotherapy and apatinib plus docetaxel treatment, with progression-free survival durations of 5 months and 6 months, respectively. This case indicated that apatinib monotherapy or apatinib plus docetaxel might be regarded as a therapeutic option for heavily pretreated patients with advanced non-squamous NSCLC.
AB - Although targeted therapy directed toward driver mutations has produced a significant efficacy benefit for patients with non-small cell lung cancer (NSCLC), many patients do not possess mutations associated with the approved targeted drugs. Angiogenic agents play an important role in the therapeutic strategy for advanced NSCLC. Apatinib is a novel tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2. A phase II clinical trial demonstrated the survival benefit of apatinib monotherapy in advanced NSCLC. Moreover, addition of anti-angiogenic agents to chemotherapy showed robust efficacy in advanced NSCLC, regardless of tumor histology. Here, we present the case of a heavily pretreated lung adenocarcinoma patient who was treated with apatinib and apatinib continuation plus docetaxel re-challenge. He was negative for several driver genes, including EGFR, ALK, KRAS, ROS1, HER2, RET and BRAF. The previous treatment included platinum-based doublets, pemetrexed monotherapy, docetaxel plus bevacizumab, gefitinib monotherapy, nab-paclitaxel monotherapy, irinotecan plus oxaliplatin and radiotherapy. He obtained a partial response after both apatinib monotherapy and apatinib plus docetaxel treatment, with progression-free survival durations of 5 months and 6 months, respectively. This case indicated that apatinib monotherapy or apatinib plus docetaxel might be regarded as a therapeutic option for heavily pretreated patients with advanced non-squamous NSCLC.
KW - Apatinib
KW - case report
KW - docetaxel
KW - heavy pretreatment
KW - non-squamous non-small cell lung cancer
KW - partial response
KW - progression-free survival
UR - http://www.scopus.com/inward/record.url?scp=85040962706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040962706&partnerID=8YFLogxK
U2 - 10.1080/15384047.2017.1414757
DO - 10.1080/15384047.2017.1414757
M3 - Article
C2 - 29261000
AN - SCOPUS:85040962706
SN - 1538-4047
VL - 19
SP - 141
EP - 144
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 3
ER -